Table 3. Lung function development in relation to asthma debut, duration, and remission.
Measure | N | Difference (95% CI) | p-Value |
---|---|---|---|
z-Score before diagnosis relative to children never developing asthma | |||
FEVz before diagnosis# | 93 | −0.29 (−0.49; −0.09) | 0.004 |
MMEFz before diagnosis# | 93 | −0.40 (−0.60; −0.20) | <0.001 |
sRawz before diagnosis# | 32 | +0.33 (+0.10; +0.57) | 0.006 |
PDz before diagnosis# | 87 | −0.35 (−0.59; −0.12) | 0.003 |
Change in z-score per year duration of asthma | |||
FEVz development# | 92 | +0.02 (−0.02; +0.07) | 0.36 |
MMEFz development# | 92 | −0.01 (−0.05; +0.03) | 0.68 |
sRawz development# | 89 | −0.02 (−0.06; +0.03) | 0.43 |
PDz development# | 87 | −0.04 (−0.10; +0.03) | 0.27 |
Change in z-score per year after remission of asthma | |||
FEVz development# | 54 | +0.02 (−0.03; +0.06) | 0.44 |
MMEFz development# | 54 | −0.00 (−0.04; +0.04) | 0.98 |
sRawz development# | 51 | +0.01 (−0.03; +0.06) | 0.54 |
PDz development# | 48 | +0.00 (−0.07; +0.08) | 0.92 |
Significant p-values in bold.
#Mixed models.
FEV, forced expiratory volume; MMEF, maximal mid-expiratory flow; PD, provocative dose of methacholine; sRaw, specific airway resistance.